dc.creator | Salto Alejandre, Sonsoles | es |
dc.creator | Palacios-Baena, Zaira R. | es |
dc.creator | Arribas, José Ramón | es |
dc.creator | Berenguer, Juan | es |
dc.creator | Carratalà, Jordi | es |
dc.creator | Jarrín, Inmaculada | es |
dc.creator | Ryan, Pablo | es |
dc.creator | Miguel Montero, Marta de | es |
dc.creator | Rodríguez-Baño, Jesús | es |
dc.creator | Pachón Díaz, Jerónimo | es |
dc.date.accessioned | 2022-09-27T14:46:03Z | |
dc.date.available | 2022-09-27T14:46:03Z | |
dc.date.issued | 2022 | |
dc.identifier.citation | Salto Alejandre, S., Palacios-Baena, Z.R., Arribas, J.R., Berenguer, J., Carratalà, J., Jarrín, I.,...,Pachón Díaz, J. (2022). Impact of early interferon-β treatment on the prognosis of patients with COVID-19 in the first wave: A post hoc analysis from a multicenter cohort. Biomedicine & pharmacotherapy, 146, 1-10. | |
dc.identifier.issn | 0753-3322 | es |
dc.identifier.issn | 1950-6007 | es |
dc.identifier.uri | https://hdl.handle.net/11441/137405 | |
dc.description.abstract | Background: Interferon-β is an attractive drug for repurposing and use in the treatment of COVID-19, based on its
in vitro antiviral activity and the encouraging results from clinical trials. The aim of this study was to analyze the
impact of early interferon-β treatment in patients admitted with COVID-19 during the first wave of the pandemic.
Methods: This post hoc analysis of a COVID-19@Spain multicenter cohort included 3808 consecutive adult pa tients hospitalized with COVID-19 from 1 January to 17 March 2020. The primary endpoint was 30-day all-cause
mortality, and the main exposure of interest was subcutaneous administration of interferon-β, defined as early if
started ≤ 3 days from admission. Multivariate logistic and Cox regression analyses were conducted to identify the
associations of different variables with receiving early interferon-β therapy and to assess its impact on 30-day
mortality. A propensity score was calculated and used to both control for confounders and perform a matched
cohort analysis.
Results: Overall, 683 patients (17.9%) received early interferon-β therapy. These patients were more severely ill.
Adjusted HR for mortality with early interferon-β was 1.03 (95% CI, 0.82–1.30) in the overall cohort, 0.96
(0.82–1.13) in the PS-matched subcohort, and 0.89 (0.60–1.32) when interferon-β treatment was analyzed as a
time-dependent variable. Conclusions: In this multicenter cohort of admitted COVID-19 patients, receiving early interferon-β therapy after
hospital admission did not show an association with lower mortality. Whether interferon-β might be useful in the
earlier stages of the disease or specific subgroups of patients requires further research. | es |
dc.format | application/pdf | es |
dc.format.extent | 10 p. | es |
dc.language.iso | eng | es |
dc.publisher | Elsevier France - Editions scientifiques medicales Elsevier | es |
dc.relation.ispartof | Biomedicine & pharmacotherapy, 146, 1-10. | |
dc.rights | Attribution-NonCommercial-NoDerivatives 4.0 Internacional | * |
dc.rights.uri | http://creativecommons.org/licenses/by-nc-nd/4.0/ | * |
dc.subject | Interferon-β | es |
dc.subject | Treatment | es |
dc.subject | COVID-19 | es |
dc.subject | SARS-CoV-2 | es |
dc.subject | Mortality | es |
dc.title | Impact of early interferon-β treatment on the prognosis of patients with COVID-19 in the first wave: A post hoc analysis from a multicenter cohort | es |
dc.type | info:eu-repo/semantics/article | es |
dcterms.identifier | https://ror.org/03yxnpp24 | |
dc.type.version | info:eu-repo/semantics/publishedVersion | es |
dc.rights.accessRights | info:eu-repo/semantics/openAccess | es |
dc.contributor.affiliation | Universidad de Sevilla. Departamento de Medicina | es |
dc.relation.publisherversion | https://www.sciencedirect.com/science/article/pii/S0753332221013597?via%3Dihub | es |
dc.identifier.doi | 10.1016/j.biopha.2021.112572 | es |
dc.journaltitle | Biomedicine & pharmacotherapy | es |
dc.publication.volumen | 146 | es |
dc.publication.initialPage | 1 | es |
dc.publication.endPage | 10 | es |